
    
      This is a multinational, 2-arm study. Patients in 1 arm receive BMS-232632 plus EFV placebo
      capsules. Patients in the other arm receive EFV plus BMS-232632 placebo. Both arms also
      receive a fixed dose of ZDV-3TC.
    
  